Xi'an Jansen biologics Starano is on the market

Johnson and Johnson's Pharmaceutical subsidiary in China, Xi'an Jansen Pharmaceutical Co., Ltd., announced that the world's first all-human source "dual-target" leukatocin 12 (IL-12) and leurium interleulin 23 (IL-23) inhibitor Starano ® (STELARA®), or Usnu monoantigen injection, has been listed in China. The Starano® is an innovative drug administration model -- a biological agent injected subcute every three months during maintenance periods for the treatment of patients with severe plaque-like psoriasis in adult adults who should not be answered for treatment of other systems such as cyclosporine, methotrexate (MTX) or PUVA (orthopedic lipids and ultraviolet A).The Starano® is an all-human monoclonal antibody targeted at IL-12 and IL-23, which inhibits these two cytokines that play a key role in the occurrence and development of psoriasis by binding to p40 protein sub-units common to IL-12 and IL-23.The results of two randomized, double-blind, placebo-controlled Phase III clinical trials, PHOENIX 1 and PHOENIX 2, involving 1996 patients, showed that The Starano® long-term efficacy was long-lasting, maintaining skin loss removal and improving quality of life for up to 5 years. Another Phase III clinical trial, LOTUS, for Chinese groups, showed that 82.5 percent (132/60) of patients using Starano ® reached the main endpoint of the trial, PASI75, at 12 weeks, and 11.1 percent in the placebo group. All key secondary endpoints also improved significantly, including more than 80 percent of patients using ® reached PASI90 at 28 weeks.In addition, PHOENIX Extended Extended Study 4® showed that The Starino ® maintains a long-term clinical response to psoriasis and that dose-related or cumulative toxicity was not observed as The Starino ® treatment time was extended. The real-world PSOLAR study, which included data on more than 12,000 patients using Stardano ® and other treatment options over an eight-year period, was consistent with the overall safety of Starino ®. In addition, several real-world registered studies have shown that Starano® has a higher overall drug retention rate and a lower risk of drug suspension than other biologics included in the study.At present, Starano has ® China, covering Beijing, Shanghai and Guangzhou and other cities. (U.S. News Agency)